Pancreatic Cancer Therapy Market Scope And Analysis

Pancreatic Cancer Therapy Market Report Scope

Pancreatic Cancer Therapy Market News and Recent Developments

The Pancreatic Cancer Therapy Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for neurointerventional devices and strategies:

• Focal Medical received the US Food and Drug Administration (FDA) clearance for its investigational new drug application for ACT-IOP-003. ACT-IOP-003 is a pancreatic cancer drug in Phase 1b of clinical trial. ACT-IOP-003 is an implantable iontophoretic product that deliver high levels of gemcitabine directly to the pancreas. (Source: Verdict Media Limited, Press Release, 2024)
• The FDA approved irinotecan liposome (Onivyde) with oxaliplatin, fluorouracil, and leucovorin, for the first-line treatment of metastatic pancreatic adenocarcinoma. The drug Onivyde is manufactured by Ipsen Biopharmaceuticals Inc. (Source: FDA, Press Release, 2024)

Pancreatic Cancer Therapy Market Report Coverage and Deliverables

The “Pancreatic Cancer Therapy Market Size and Forecast (2023–2031)” report provides a detailed analysis of the market covering below areas:

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Market dynamics such as drivers, restraints, and key opportunities
• Key future trends
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
• Detailed company profiles